APA (7th ed.) Citation

C, S., L, C., V, R., R, G., CH, G., HC, K., . . . M, C. (2025). Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Blood cancer journal, 15(1), 78. https://doi.org/10.1038/s41408-025-01241-9

Chicago Style (17th ed.) Citation

C, Sarkozy, et al. "Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study." Blood Cancer Journal 15, no. 1 (2025): 78. https://doi.org/10.1038/s41408-025-01241-9.

MLA (9th ed.) Citation

C, Sarkozy, et al. "Validation of POD24 as a Robust Early Clinical Indicator of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials, a LYSA Study." Blood Cancer Journal, vol. 15, no. 1, 2025, p. 78, https://doi.org/10.1038/s41408-025-01241-9.